Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Immune System Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma

Hypersensitivity

Adenocarcinoma of Lung

Lung Adenocarcinoma

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Amino Acids

Carboplatin

Pemetrexed

Gefitinib

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Folinic Acid

Folate

Vitamin B9

Tyrosine

pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks

pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.

received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death

pemetrexed plus carboplatin

gefitinib

Baohui Han, Dr

Bo Jin, Dr

Yanjie Niu, Master

Yanwei Zhang, Dr

Tianqing Chu, Dr

Aiqin Gu, Master

Lei Zhu, Master

Jun Pei

The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators need a head-to-head study to reply.

Combination of Chemotherapy and Gefitinib as First-line Treatment

Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

Toxicity will be graded according to NCI CTCAE, version 4.0. The analysis of safety/tolerability data will be descriptive; toxicity events will be individually tabulated.

Baohui Han

the chief physician

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combination of Chemotherapy and Gefitinib as First-line Treatment	NCT02148380	Non-Small-Cell ...	pemetrexed plus... gefitinib	18 Years - 65 Years	Shanghai Chest Hospital
Combination of Chemotherapy and Gefitinib as First-line Treatment	NCT02148380	Non-Small-Cell ...	pemetrexed plus... gefitinib	18 Years - 65 Years	Shanghai Chest Hospital

Spots Global Cancer Trial Database for lung adenocarcinoma,egfr mutation, chemotherapy, gefitinib